{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T05:24:30Z","timestamp":1698125070454},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":4939,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1991,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To elucidate the mechanism by which carbamazepine lowers somatostatin concentration in cerebrospinal fluid of humans, the effect of carbamazepine on secretion of this peptide was studied in rat cerebral cell cultures. Concentrations of carbamazepine within the therapeutic range (4 \u00d7 10<jats:sup>\u22125<\/jats:sup> M) inhibited spontaneous release of somatostatin and blocked secretory responses to the epileptogen, picrotoxin, and to the cyclic cAMP stimulator forskolin. One of the proposed mechanisms of carbamazepine action is that it binds to adenosine receptors, but in this study, aminophylline, an adenosine antagonist, in a concentration as high as 2.4 \u00d7 10<jats:sup>\u22124<\/jats:sup> M, did not reverse carbamazepine effects. Carbamazepine suppression of picrotoxin, however, was overcome by exposure to veratridine, a sodium channel\u2010active compound. This finding supports the hypothesis that carbamazepine acts by binding to sodium channels. Phenytoin, another anticonvulsant with many similar properties, also blocked picrotoxin\u2010induced somatostatin release at a concentration of 10<jats:sup>\u22124<\/jats:sup> M, and its effects were also reversed by veratridine at a concentration of 10<jats:sup>\u22125<\/jats:sup> M. These findings clarify the mechanism by which carbamazepine and phenytoin act in epilepsy and trigeminal neuralgia.<\/jats:p>","DOI":"10.1002\/ana.410290412","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T11:59:54Z","timestamp":1104580794000},"page":"413-417","source":"Crossref","is-referenced-by-count":3,"title":["Carbamazepine and phenytoin inhibit somatostatin release from dispersed cerebral cells in culture"],"prefix":"10.1002","volume":"29","author":[{"given":"Seymour","family":"Reichlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Mothon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"595","article-title":"Carbamazepine update","volume":"2","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_1_3_2","series-title":"GABA and mood disorders. L.E.R.S. Monograph Series","first-page":"201","volume-title":"Carbamazepine in affective illness: implications for GABA mechanisms","author":"Post RM","year":"1986"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198906000-00003"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00428416"},{"key":"e_1_2_1_6_2","first-page":"115","article-title":"Relationship between cerebrospinal fluid somatostatin and peripheral thyroid hormones with carbamazepine treatment","volume":"14","author":"Joffe RT","year":"1985","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1986.tb04640.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(82)90877-0"},{"key":"e_1_2_1_9_2","first-page":"71","article-title":"Biochemical pharmacology of the GABA receptor\u2010ionophore protein complex","volume":"37","author":"Stephenson FA","year":"1983","journal-title":"Adv Biochem Psychopharmacol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1523\/JNEUROSCI.06-04-01171.1986","article-title":"Cyclic AMP regulates somatostatin mRNA accumulation in primary diencephalic cultures and in transfected fibroblast cells","volume":"6","author":"Montminy MR","year":"1986","journal-title":"J Neurosci"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)91549-1"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(89)80008-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1983.tb03429.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90135-8"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.9.3051"},{"key":"e_1_2_1_16_2","unstructured":"RichardsonSB TwenteS.Somatostatin release from dispersed rat neurons is inhibited by anti\u2010epileptic agents. Program 70th Annual Meeting of the Endocrine Society. New Orleans LA June 8\u201311 1988:87(Abstract)"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-102-2-523"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6629.1110"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-45619-0_3"},{"key":"e_1_2_1_20_2","first-page":"10","article-title":"Adenosine receptors and beyond; molecular mechanisms of physiological regulation","volume":"38","author":"Stiles GL","year":"1990","journal-title":"Clin Res"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-2-496"},{"key":"e_1_2_1_22_2","first-page":"448","volume-title":"The pharmacological basis of therapeutics","author":"Rall TW","year":"1980"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(90)90117-N"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-3806(88)90011-9"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(76)90063-0"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-103-3-912"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90366-1"},{"key":"e_1_2_1_28_2","unstructured":"VecseiL WiderlovE.Preclinical and clinical studies with somatostatin related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry1990(in press)"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-109-6-2255"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1523\/JNEUROSCI.02-02-00225.1982","article-title":"Depletion of somatostatin\u2010like immunoreactivity in the rat central nervous system by cysteamine","volume":"2","author":"Sagar SM","year":"1982","journal-title":"J Neurosci"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","unstructured":"VecseiL WiderlovE.Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry1990(in press)","DOI":"10.1016\/0278-5846(90)90072-O"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91657-4"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90169-5"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410210511"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1523\/JNEUROSCI.03-06-01176.1983","article-title":"Effects of somatostatin on mammalian cortical neurons in culture: physiological actions and unusual dose response characteristics","volume":"3","author":"Delfs JR","year":"1983","journal-title":"J Neurosci"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90030-5"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1977.tb04474.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.5.3260"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(80)90156-9"},{"key":"e_1_2_1_40_2","first-page":"627","article-title":"Inhibition of binding of [3H]batrachotoxinin A 20\u2010alpha\u2010benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine","volume":"22","author":"Willow M","year":"1982","journal-title":"Mol Pharmacol"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410290412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410290412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T05:54:31Z","timestamp":1698040471000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410290412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1991,4]]}},"alternative-id":["10.1002\/ana.410290412"],"URL":"https:\/\/doi.org\/10.1002\/ana.410290412","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,4]]}}}